The attorneys and technical specialists who make up the global life sciences group understand the unique needs of a wide range of clients in the dynamic life sciences industry. We work across practices and geographies to develop cutting-edge solutions that help our clients meet their business goals.
In addition to advising biotechnology, pharmaceutical and medical device companies, we also work with:
- Investment banks, venture capital and private equity firms, royalty monetization firms, private investment and hedge funds, and individual investors focused on funding life sciences-related companies
- Food, dietary supplement, cosmetics and consumer product companies
- Academic medical centers and research institutions
- Veterinary, agricultural and industrial applications
Drawing on resources in our offices around the globe, we focus on developing cutting-edge solutions to help clients meet their business goals. Our practice includes:
Ropes & Gray’s life sciences team has handled every type of transaction from licensing agreements with a small biotechnology company to large mergers of industry-leading pharmaceutical and medical device companies around the globe. Recent noteworthy transactions include representation of:
- Pfizer on its $14 billion acquisition of Medivation Inc., a biopharmaceutical company focused on developing and commercializing small molecules for oncology.
- Shire in its agreement with Baxalta Incorporated to combine the companies for an aggregate consideration of approximately $32 billion. Baxalta, headquartered in Northern Illinois, is a $6 billion global biopharmaceutical leader developing, manufacturing and commercializing therapies for orphan diseases and underserved conditions in hematology, oncology, and immunology.
- Boehringer Ingelheim in a $595 million global license and collaboration agreement with AbbVie to jointly develop and commercialize a biologic IL-23 antibody for the treatment of psoriasis and other immunological indications.
- Vertex Pharmaceuticals in its $2.6 billion strategic research and collaboration agreement with CRISPR Therapeutics.
- Pacira Pharmaceuticals in First Amendment and APA challenges to FDA’s assertions that the company engaged in “off-label” promotion of its flagship product, a post-surgical analgesic. As a result, FDA agreed to withdraw its warning letter and revise the label to clarify that the challenged claims were permissible.
- The Broad Institute of MIT and Harvard in a global licensing agreement with Monsanto Company for the use of the CRISPR-Cas genome-editing technology in agriculture. The agreement is the Broad Institute’s first commercial license for use of the CRISPR technology in agriculture.
- Pfizer on its definitive agreement to acquire Hospira, an Illinois-based leading provider of injectable drugs and infusion technologies, for approximately $17 billion in the all-cash deal.
- Novavax Inc., a clinical-stage vaccine company, which focuses on discovering, developing, and commercializing recombinant nanoparticle vaccines and adjuvants, in its $300 million convertible notes offering.
- Sarepta Therapeutics in its $584 million exclusive license and collaboration agreement with Summit Therapeutics for the European rights to Summit’s utrophin modulator pipeline for the treatment of Duchenne Muscular Dystrophy.
- Cubist Pharmaceuticals in connection with its $9.5 billion sale to Merck.
- Wright Medical Technology in its $3.3 billion merger with Tornier NV, creating a new company to be called Wright Medical Group NV, based in the Netherlands. Proteostasis Therapeutics in a $1.2 billion worldwide collaboration deal to develop and commercialize Infinity’s duvelisib for the treatment of patients with cancer.